The FULCRUM-VT trial evaluated the clinical utility of ultra-low temperature ablation for treating ventricular tachycardia in ...
In seven patients, there were no signs of toxicity with proton-beam radioablation, clearing the way for future studies.
In the single-arm FULCRUM-VT trial, 59% of patients remained free of recurrent VT at 6 months, with less amiodarone use.
Proton beam therapy, a radiation treatment for cancer, may be effective as a treatment for refractory ventricular tachycardia ...
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; “Adagio Medical”, “Adagio” or the “Company”), a leading innovator in catheter ablation technologies, today announced ...
LAGUNA HILLS, Calif., Sept. 13, 2023 /PRNewswire/ -- Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), ...
A new technology using ultralow temperature cryoablation (ULTC) has eliminated clinical ventricular tachycardia (VT) in 94% of patients. The late-breaking science is presented at EHRA 2024, a ...
Medical Device Network on MSN
Adagio Medical reports positive six-month results in FULCRUM-VT trial
The trial is evaluating the vCLAS cryoablation system at 20 centres across Canada and the US.
Ventricular tachycardia, or V-tach (VT), and supraventricular tachycardia (SVT) are two types of tachycardia. The term “tachycardia” refers to a heart rate of more than 100 beats per minute. The key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results